Please assess the completion status of the following clinical trial:

Trial Title: Active Preoperative Anemia Management in Patients Undergoing Cardiac Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* between the age of 18 and 80 years old~* diagnosed with preoperative anemia, defined as hemoglobin \<13.0 grams per deciliter (g/dL)~* scheduled for elective cardiac surgery (CABG, valve, or CABG/valve), including both first time and repeat procedures~* documented negative pregnancy test within 7 days prior to the procedure for females of child-bearing potential~* a written informed consent prior to any procedure, using a form that is approved by the UT Southwestern Institutional Review Board~* agreement to be compliant~Exclusion Criteria:~* uncontrolled hypertension (defined as systolic pressure greater than 180 millimeters of mercury (mmHg), diastolic pressure greater than 100mmHg, not adequately controlled by anti-hypertensive therapy at the time of procedure)~* current renal failure on dialysis or serum creatinine \>3.0 milligrams per deciliter (mg/dL)~* unstable angina (defined by chest pain and EKG changes indicating ischemia at rest)~* thromboembolism within the past year~* current active primary or metastatic malignancy or history of myeloid malignancy~* seizures within the past year~* history of stroke within the last 6 months~* patients who have platelet count lower than 50,000 per cubic millimeter (mm3) or coagulation abnormality~* sepsis or bacteremia defined by positive blood culture~* patients who have known hypersensitivity to EPO or any of its components~* patients who have known hypersensitivity to Feraheme or any of its components~* patients who refuse blood transfusion, (i.e. Jehovah's Witnesses)~* pregnant or breast feeding~* patients who are unable to provide informed consent or who has inability to understand or corporate with study procedure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- EPO and Feraheme (Type: ACTIVE_COMPARATOR): Patients in the treatment group will receive a subcutaneous injection of EPO 300U/kg at the Baseline visit, the Preoperative visit and on POD 2; and an infusion of Feraheme 510mg at the Baseline visit and the Preoperative visit.
- Control (Type: NO_INTERVENTION): The control group will receive no preoperative intervention for anemia. The exception being iron deficiency anemia found during baseline. If laboratory values indicate iron deficiency, oral iron will be recommended to take until surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).